Evidence map›Paper›PMID 40543052›Full record

ArticleCancer2025

Transmission ratio distortion of germline TP53 variants in Li-Fraumeni syndrome families.

Naama Halpern, Iris Kventsel, Gal Strauss, Yehudit Peerless, Ben Boursi, Michal Yalon, Yael Goldberg, Inbal Kedar, Hagit Shani, Eitan Friedman and 1 more

Erratum issuedAbstract read
In one paragraph

Article in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Naama HalpernThe Jusidman Cancer Center, Sheba Medical Center, Ramat Gan, Israel.ORCID https://orcid.org/0000-0002-8926-4154
Iris KventselDepartment of Pediatric Hemato-Oncology, Edmond and Lilly Safra Children's Hospital and Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel.
Gal StraussThe Jusidman Cancer Center, Sheba Medical Center, Ramat Gan, Israel.
Yehudit PeerlessThe Jusidman Cancer Center, Sheba Medical Center, Ramat Gan, Israel.
Ben BoursiThe Jusidman Cancer Center, Sheba Medical Center, Ramat Gan, Israel.ORCID https://orcid.org/0000-0002-1304-8340
Michal YalonDepartment of Pediatric Hemato-Oncology, Edmond and Lilly Safra Children's Hospital and Cancer Research Center, Sheba Medical Center, Ramat Gan, Israel.
Yael GoldbergFaculty of Medical and Health Sciences, School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Inbal KedarThe Recanati Genetics Unit, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel.
Hagit ShaniPreimplantation Genetic Diagnosis Center, Danek Gertner Institute of Human Genetics, Sheba Medical Center, Ramat Gan, Israel.
Eitan FriedmanFaculty of Medical and Health Sciences, School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Rinat Bernstein-MolhoThe Jusidman Cancer Center, Sheba Medical Center, Ramat Gan, Israel.ORCID https://orcid.org/0000-0002-4068-9514

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLi-Fraumeni syndrome (LFS) is a rare autosomal-dominant cancer-predisposition syndrome caused by germline pathogenic or likely pathogenic variants (P/LPVs) in the TP53 gene. Classical autosomal-dominant inheritance predicts a 50% transmission rate of TP53 P/LPV from each carrier parent to their offspring. However, clinical observations suggest higher-than-expected carrier proportions, indicating a potential transmission ratio distortion (TRD). The objective of this study was to investigate TRD in Israeli LFS families.

methodsData from families with an LFS diagnosis who were followed at Sheba Medical Center between 2015 and 2024 were reviewed. Families that had complete clinical data and offspring were included. Pedigree analyses classified carriers as confirmed, obligate, or probable. Observed carrier proportions were compared with the expected 50% rate using one-sample t-tests.

resultsAmong 171 individuals from 20 families, 100 (58.5%) were identified as TP53 P/LPV confirmed or obligatory carriers, significantly exceeding the expected 50% inheritance rate (p = .027). A second analysis, which included 11 probable carriers, resulted in a carrier proportion of 64.9% (p < .001). TRD was observed across all phenotypic groups. No significant differences in TRD were observed by sex or variant type.

conclusionsThis study revealed significant TRD in TP53 P/LPV inheritance among Israeli LFS families. A potential mechanism involves the role of TP53 in the cell cycle, in which reduced TP53 function may enhance embryonic cell proliferation, offering a survival or implantation advantage. TRD in LFS has implications for genetic counseling, reproductive decision making, and clinical management. These findings underscore the need for further research to validate TRD across diverse populations and elucidate the underlying mechanisms.

Indexed as

Germ-Line MutationLi-Fraumeni SyndromeTumor Suppressor Protein p53AdolescentAdultChildFemaleGenetic Predisposition to DiseaseHeterozygoteHumansIsraelMaleMiddle AgedPedigreeTP53 protein, humanTumor Suppressor Protein p53hereditary cancer syndromesLi–Fraumeni syndromeTP53transmission ratio distortion

Identifiers

PMID40543052
PMCPMC12182265

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.